Authors
Latest:
cUTI Roundtable: The Latest Therapeutic DevelopmentsThe third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Latest:
Molecular Diagnostics for Bacterial Pneumonia Need Testing StewardshipOngoing education and proven outcomes need to aid this form of testing.
Latest:
An Update on LenacapavirThis new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
Latest:
Communication Breakdown: Dissemination of Public Health InformationImprecise language can fuel infodemics and misinformation and damage public trust.
Latest:
To Prophylax or not to Prophylax: Preventing CDIClinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
Latest:
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Latest:
Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful ProgramThis form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
Latest:
Going Viral on Social Media: Integrating Digital Tools into Pharmacy RotationsIn the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Latest:
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Latest:
Tricky Infusion Issues and Potential Solutions: OPAT EditionOutpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
Latest:
Treating Zaire ebolavirus With Ansuvimab-zyklThe recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
Latest:
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii PneumoniaHere is a review of using this therapy in this patient population.
Latest:
New Recommendations for Antibiotic Prophylaxis Prior to Dental ProceduresThe American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.
Latest:
Precision Dosing of To-Marrow: Linezolid Therapeutic Drug MonitoringEmerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
Latest:
Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
Latest:
From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination StrategiesThis indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Latest:
Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent IllnessVery few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Latest:
PrEP State of the Union: Adherence, Access, Uptake IssuesAlthough this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
Latest:
Antibiotic De-Escalation: Is This the Right Outcome Measure?The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
Latest:
Ceftriaxone as Definitive OPAT for MSSA Bloodstream InfectionsA cautious approach for now is warranted as well as a need for a randomized clinical trial.
Latest:
Employee Health After the COVID-19 Pandemic: Stronger Than YesterdayFor providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
Latest:
Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream InfectionsWith potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
Latest:
Strengths and Limitations of T2Candida Implementation From an Antimicrobial Stewardship PerspectiveThis novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.
Latest:
Clinical Considerations in Conducting Antifungal Susceptibility TestingAccess to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
Latest:
What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Latest:
Weekly Flu Report Finds Sporadic InfectionsThis flu season, the CDC reported at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far.
Latest:
Recent Research Indicates That We're Falling Short on HBV Elimination TargetsOrganizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
Latest:
The Variety of Variants in COVID-19The evolution of the major variants, including the delta mutation.
Latest:
Practice Pearls for Treatment of Respiratory InfectionsTina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
